A running index of strategic reviews and exploration of alternatives covered in the Special Situations Digest. Below are recent strategic review announcements, board-authorized exploration of alternatives, and special committee formations across global markets, with each item linked to the underlying filing. Below: the 100 most recent situations spanning 19 countries. Earlier coverage includes 289+ additional situations from prior issues.
Strategic reviews are explicit, board-authorized signals that the company is open to a transformation: sale, merger, spin-off, recapitalization, or liquidation. The announcement itself often catalyzes immediate price action, but the more sophisticated trade is identifying which reviews will result in a transaction versus which will conclude with 'no action.' Activist pressure, fiscal stress, and CEO turnover are common precursors that change the base rate.
The full weekly digest covers 30+ countries and 250-500 situations per issue across all categories, with Excel/PDF/JSON exports and an LLM-ready format. Subscribe for full access.
Jump to country
United States 43 situations
CID HoldCo, Inc. DAIC (US) · $2.42 · MCAP $3M · EV $4M
Dot Ai (CID Holdco Inc.) provides IoT and AI-driven digital transformation technology for sectors including aviation, construction, military, and retail.
Dot Ai (DAIC) has initiated a board-authorized review of strategic alternatives, including a potential sale, merger, partnership, recapitalization, or liquidation. The company appointed Cohen & Company Capital Markets as its exclusive financial advisor for the full-company process. Dot Ai, a provider of AI-driven digital transformation technology with a $3M market cap, reported negative earnings and no insider trading activity over the last 12 months. The engagement of a sell-side advisor for this distressed nano-cap suggests a probable sale or wind-down, creating a binary catalyst between a going-private transaction at a control premium or a liquidation likely to leave minimal residual equity value.
Featured in Issue #18 ·
CollPlant Biotechnologies Ltd. CLGN (US) · $0.39 · MCAP $6M · EV $4M
EV/Sales: 2.0x · EV/GP: 7.8x (FY2026)
CollPlant Biotechnologies develops recombinant human collagen (rhCollagen) using a proprietary plant-based expression platform. Its lead preclinical program is a dermal-filler product for medical aesthetics, and it previously partnered with AbbVie's Allergan on filler development.
CollPlant Biotechnologies Ltd. (CLGN) is conducting a strategic review of alternatives including potential acquisitions, strategic transactions, or business combinations. The board is currently in discussions with several aesthetics players following the April 2026 termination of a dermal-filler co-development agreement with AbbVie's Allergan. CollPlant ended Q1 2026 with $4.3 million in cash against a $3.0 million quarterly operating cash burn, while quarterly GAAP revenue declined to $73,000. Nasdaq has set a September 21, 2026, deadline for the company to regain compliance with the $1.00 minimum bid price rule. The firm faces a narrow window before cash exhaustion to execute a reverse split, dilutive rescue financing, or a strategic transaction that could re-rate the rhCollagen platform if credible aesthetics partners emerge.
Featured in Issue #18 ·
Jasper Therapeutics, Inc. JSPR (US) · $0.53 · MCAP $15M · EV $2M
EV/Sales: 1.4x (FY2026)
Jasper Therapeutics is a clinical-stage biotech developing briquilimab, an anti-c-Kit monoclonal antibody, for mast cell-driven diseases including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
Jasper Therapeutics, Inc. (JSPR) announced on June 1, 2026, that its board has initiated a comprehensive review of strategic alternatives. The process will consider a potential sale of the company, merger, asset sale, licensing, or an orderly wind-down. The clinical-stage biotechnology company is simultaneously implementing cost-saving measures to preserve cash and maintain regulatory compliance while conducting the review, which has no defined completion timeline. The explicit inclusion of an orderly wind-down as a strategic alternative requires an assessment of the company's cash runway against its enterprise value to determine the downside floor.
Featured in Issue #18 ·
Sensei Biotherapeutics, Inc. SNSE (US) · $14.65 · MCAP $20M
Clinical-stage oncology company developing immunotherapies for cancer. Its pipeline includes solnerstotug and PIKTOR, targeting PD-(L)1 resistant tumors.
Sensei Biotherapeutics announced the initiation of a strategic review process to maximize shareholder value via an 8-K filing. The company previously completed the acquisition of Faeth Therapeutics, adding acquired-business financials and pro forma data to its filings. Sensei is a clinical-stage oncology company with its lead assets PIKTOR and solnerstotug targeting PD-(L)1 resistant tumors.
Featured in Issue #18 ·
Werewolf Therapeutics, Inc. HOWL (US) · $0.45 · MCAP $22M
EV/EBITDA: 0.2x · EV/GP: 0.3x
Werewolf Therapeutics develops conditionally activated immuno-oncology therapies using its INDUKINE and INDUCER platforms, designed to activate only in the tumor microenvironment to reduce systemic toxicity.
Werewolf Therapeutics, Inc. (HOWL) is exploring strategic options to maximize shareholder value and has engaged Piper Sandler as its advisor. The company held $46.5 million in cash as of March 31, 2026, but warned of substantial doubt regarding its ability to continue as a going concern without additional capital. Recent corporate actions include the acquisition of the JZP898 program rights by Jazz Pharmaceuticals for $21 million and the subsequent use of $31.4 million in proceeds to repay a loan from K2 HealthVentures. Between May 27 and May 29, 2026, entities affiliated with director Luke Evnin sold 141,106 shares under a Rule 10b5-1 plan. The stock now trades as a cash-and-deal-premium play where the next catalyst is a process update or announcement regarding a potential sale of the remaining INDUKINE and INDUCER pipeline or a reverse merger.
Featured in Issue #18 ·
America's Car-Mart Inc. CRMT (US) · $7.73 · MCAP $64M · EV $899M
Fwd P/E: 74.8x · EV/EBITDA: 7.9x · EV/Sales: 0.7x · EV/GP: 1.4x (FY2027)
Operates a buy-here-pay-here used auto dealership chain focused on subprime borrowers. Sells and finances older used vehicles through its network of company-owned lots primarily in the South and Midwest.
America's Car-Mart, Inc. (CRMT) formed a special committee to explore strategic alternatives, including mergers and acquisitions, and engaged Houlihan Lokey Capital Inc. as financial advisor. The company appointed Adam Paul of AP Advisors LLC as a new board director and chair of the committee to oversee the review. America's Car-Mart shuttered 42 locations in April 2026, reducing its store footprint by 44 percent since late 2025, and reported a loss of more than $104 million during the first three quarters of fiscal 2026. This formal evaluation follows an 86 percent share price decline over 12 months as the company experienced deterioration in subprime credit performance. With an enterprise value of $899 million against a $64 million market capitalization, the focus for the distressed situation centers on bondholder recoveries and any potential going-concern sale premium.
Featured in Issue #18 ·
Nano Dimension Ltd. NNDM (US) · $1.63 · MCAP $339M · EV -$83M
Nano Dimension delivers advanced digital manufacturing technologies to defense, aerospace, automotive, electronics, and medical-device industries, focusing on high-mix, low-volume production with IP security. The company is a post-acquisition rollup now rationalizing disparate product lines.
Nano Dimension Ltd. (NNDM) issued a strategic review update via a DEFA14A filing, narrowing Phase 3 of its process to a small subset of high-growth alternatives with an announcement expected in the coming weeks. The company launched the review in September 2025 with financial advisors Guggenheim Securities, LLC and Houlihan Lokey, Inc. Phase 2 monetization efforts yielded the $42.5M all-cash sale of Markforged to Stratasys and a $2M upfront sale of the AME/Fabrica product lines. As of March 31, 2026, Nano Dimension holds approximately $441.6M in cash, equivalents, restricted deposits, and marketable securities against a $339M market capitalization. Share repurchases are currently prohibited due to material non-public information related to the ongoing process. The narrowing of alternatives signals a Phase 3 catalyst for this micro-cap trading below its cash value, where an explicit MNPI-linked buyback blackout confirms the review remains live and material.
Featured in Issue #18 ·
Fulcrum Therapeutics, Inc. FULC (US) · $6.42 · MCAP $428M · EV $100M
EV/EBITDA: 2.1x · EV/GP: 2.1x
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined diseases, with a lead program in sickle cell disease that it has now discontinued.
Fulcrum Therapeutics, Inc. (FULC) has engaged Leerink Partners as its financial advisor to conduct a review of strategic alternatives, including a potential merger, acquisition, business combination, or asset sale. The board approved a restructuring plan on May 31, 2026, that reduces the company's workforce by 85%, from 57 to nine employees, following the discontinuation of its lead sickle cell disease program. Fulcrum expects to incur approximately $4.2 million in restructuring charges, primarily for severance, which will be substantially cash-settled in the second quarter of 2026. No timeline has been established for the review process, and the company disclaims any intent to provide updates until the board approves a specific course of action. The formal advisor engagement and near-total workforce reduction signal a distressed biotech pivoting toward a full-company sale or asset monetization where the strategic outcome likely involves an IP or asset sale rather than a standalone going concern.
Featured in Issue #18 ·
Monro, Inc. MNRO (US) · $14.53 · MCAP $436M · EV $908M
Fwd P/E: 40.6x · EV/EBITDA: 7.8x · EV/Sales: 0.8x · EV/GP: 2.2x (FY2027)
Monro, Inc. is a chain of 1,115 company-operated auto service and tire centers in the United States, offering undercar repair, brake services, and tire replacement under brands like Monro Auto Service and Tire Choice.
Monro, Inc. (MNRO) disclosed that its board has initiated a strategic review of business alternatives for the full company, including a potential sale or other transaction. The review was announced alongside Q1 CY2026 results reporting a 7.2 percent year-on-year revenue decline to $273.8 million and a non-GAAP loss of $0.16 per share. The company operates 1,115 auto service and tire centers across the United States. No financial advisor has been named, and no timeline for the conclusion of the review has been established. The formal strategic review at this $436M market-cap chain puts the company in play for a potential take-private or merger situation, with weak Q1 results increasing pressure on the board to pursue a value-maximizing transaction.
Featured in Issue #18 ·
Arvinas, Inc. ARVN (US) · $8.00 · MCAP $516M · EV -$128M
EV/EBITDA: 0.3x
Arvinas is a clinical-stage biopharmaceutical company developing targeted protein degradation therapeutics (PROTACs) for oncology and neuroscience indications. Its pipeline includes both wholly-owned and partnered programs, with a lead asset in prostate cancer.
Arvinas, Inc. (ARVN) completed a strategic pipeline review and will re-prioritize its portfolio to seek an out-licensing agreement for additional clinical trials of its Phase 1 KRAS G12D asset, ARV-806. The company intends to finish the ongoing monotherapy dose escalation and share data in 2026 but will not internally fund development beyond that stage. Arvinas reported a cash runway extending into the second half of 2028, mitigating immediate financing risk. The decision to out-license signals that Arvinas lacks the internal appetite to fund a competitive pivotal program alone, making the 2026 Phase 1 readout a binary catalyst for attracting a partner or validating the PROTAC platform.
Featured in Issue #18 ·
Centerspace CSR (US) · $66.67 · MCAP $1.1B · EV $2.2B
EV/EBITDA: 14.5x · EV/Sales: 8.2x · EV/GP: NM (FY2026)
Centerspace owns and operates 61 apartment communities with 12,263 homes across Colorado, Minnesota, Montana, Nebraska, North Dakota, South Dakota, and Utah. It is an internally-managed multifamily REIT focused on providing rental housing.
Centerspace (CSR) concluded its comprehensive strategic review by approving a portfolio optimization and deleveraging plan involving $240 million to $245 million in asset sales. The plan includes the sale of 12 communities, representing a full exit from the Bismarck and Rapid City markets and one community in Denver. All 12 dispositions are currently under contract with buyers, with closings expected in H2 2026. Completion of these sales is expected to reduce total debt by $175 million to $190 million and lower proforma Net Debt to EBITDA from 8.2x to sub-7x. The strategic review outcome is an asset-sale-and-deleverage plan rather than a full-company sale, leaving the potential $45 million to $65 million special distribution later in 2026 as the key variable for PMs.
Featured in Issue #18 ·
Fortune Brands Innovations, Inc. FBIN (US) · $39.08 · MCAP $4.7B · EV $7.4B
Fwd P/E: 12.4x · EV/EBITDA: 8.9x · EV/Sales: 1.7x · EV/GP: 3.8x (FY2026)
Fortune Brands Innovations provides home, security, and digital products for residential repair, remodeling, new construction, and security applications, primarily in North America. Its platforms span plumbing, security, and outdoor living, including the Fiberon composite decking brand.
Fortune Brands Innovations, Inc. (FBIN) has initiated a formal board-level strategic review of multiple alternatives for its Fiberon composite decking business. The review occurs against a backdrop of softer US housing demand and margin pressure across the company's core plumbing, security, and outdoor platforms. Management recently emphasized capital allocation and portfolio discipline by repurchasing 3,857,831 shares through late March 2026 while Fiberon continues normal operations. This public review signals active portfolio pruning to sharpen focus on higher-return segments, where a potential sale would test buyer appetite for non-core decking assets in a soft housing cycle and could unlock capital for buybacks or debt reduction.
Featured in Issue #18 ·
A. O. Smith Corporation AOS (US) · $57.20 · MCAP $7.9B · EV $8.3B
Fwd P/E: 15.1x · EV/EBITDA: 7.9x · EV/Sales: 2.1x · EV/GP: 5.5x (FY2026)
A. O. Smith manufactures residential and commercial water heating equipment and water treatment products, with a significant operating segment in China focused on the premium market.
A. O. Smith Corporation (AOS) is conducting a strategic review of its China operations, exploring potential outcomes ranging from restructuring to an outright sale. Management expects to provide additional details on the process within the next few months. Stifel maintained a Buy rating and $75 price target on the stock, noting that the China premium segment is underperforming as consumers trade down amid weak market conditions and local competition. The shares are currently trading near 52-week lows. A sale or restructuring would remove the primary overhang on earnings, with management’s updated timeline suggesting the resolution of the China business is approaching rather than open-ended.
Featured in Issue #18 ·
BNB Plus Corp. BNBX (US) · $0.43 · MCAP $2M · EV $1M
EV/Sales: 0.2x · EV/GP: 0.4x (FY2026)
BNB Plus provides streamlined access to the Binance ecosystem through non-directional yield strategies and long BNB exposure, operating a digital asset treasury. It also owns LineaRx, a therapeutic DNA production services subsidiary serving the biopharmaceutical and diagnostics markets.
Bnb Plus Corp. (BNBX), a digital-asset treasury formerly known as Applied DNA Sciences, has launched a comprehensive strategic review to evaluate the monetization of its profitable LineaRx biotech subsidiary and the expansion of digital asset and AI infrastructure. GlobalStake Infrastructure, chaired by Silvermine founder Richard Shorten, will lead the review process. The company secured $4.1M of a targeted $5.0M convertible preferred stock financing from Silvermine Capital Advisors and other investors at $1.05 per share, representing a 176% premium to the $0.38 common price. BNBX expects to hold over $16.4M in cash and digital assets following the financing, while LineaRx achieved profitability in Q2 FY2026. The hire of an external advisor for a dual-track review alongside a high-premium financing from an insider-aligned investor group signals the company is formally in play and sets a floor on valuation expectations.
Featured in Issue #17 ·
ENDRA Life Sciences Inc. NDRA (US) · $5.50 · MCAP $4M · EV $3M
ENDRA Life Sciences develops ultrasound-based technology for imaging tissue fat content to assess and monitor non-alcoholic steatohepatitis (NASH) and other inflammatory conditions. Micro-cap medical device company listed on Nasdaq, headquarters in Ann Arbor, Michigan.
Endra Life Sciences Inc. (NDRA) entered into a Securities Purchase Agreement with an accredited investor for $3.8 million in gross proceeds through the issuance of 578,387 shares and warrants at $6.57 per unit. Lucid Capital Markets acted as the sole placement agent for the PIPE, which is intended to restore Nasdaq stockholders' equity compliance after a 2026 delisting warning. A concurrent side letter requires NDRA to segregate the purchase price in a controlled account and mandates full repayment if the company abandons pursuit of a "Potential Strategic Alternative" with identified counterparties. The agreement further grants the investor a board observer seat until a strategic deal closes or the process is terminated. The contingent repayment obligation and segregated-cash requirement signal that a specific strategic transaction is sufficiently advanced to attract capital tied to its outcome, effectively structuring the investment as a PIPE-plus-option on a potential buyout or reverse merger.
Featured in Issue #17 ·
America's Car-Mart, Inc. CRMT (US) · $12.29 · MCAP $102M · EV $937M
Fwd P/E: NM · EV/EBITDA: 8.3x · EV/Sales: 0.7x · EV/GP: 1.4x (FY2027)
America's Car-Mart operates buy-here-pay-here used car dealerships and provides in-house financing to subprime customers across the US, primarily in smaller markets. The company sells older-model vehicles and self-finances the loans, retaining significant credit risk exposure.
Americas Carmart Inc (CRMT) established a Board Special Committee on May 22 to oversee a strategic review encompassing financing, recapitalization, M&A, asset sales, and debt restructuring. The company retained Houlihan Lokey as financial advisor and appointed Adam Paul as an independent director and Special Committee Chair. Paul’s compensation is $45,000 per month plus $4,000 per day for excess time, with a minimum term of three months. The May 29 filing formally launches a review that was previously telegraphed as an ongoing evaluation. The engagement of a restructuring-capable advisor and creation of a Special Committee at a stressed subprime lender signals the board is exploring a sale, recapitalization, or debt restructuring, with the mandate explicitly including the review and modification of the company’s debt facilities.
Featured in Issue #17 ·
Monro, Inc. MNRO (US) · $16.45 · MCAP $494M · EV $935M
Fwd P/E: 43.9x · EV/EBITDA: 7.9x · EV/Sales: 0.8x · EV/GP: 2.3x (FY2027)
Monro, Inc. is one of the nation's leading automotive service and tire providers, offering oil changes, tires, parts installation, and complex vehicle repairs through a network of company-operated stores. The company generated approximately $1.2 billion in sales in fiscal 2026.
Monro, Inc. (MNRO) announced on May 27, 2026, that its board has initiated a review of strategic alternatives to maximize shareholder value. The full-company review includes potential asset sales, refinancing, strategic acquisitions, operational improvements, or a sale of the company. Monro is an automotive service and tire provider that generated approximately $1.2 billion in sales in fiscal 2026. No financial advisors have been named in connection with the review and no definitive timeline has been set for its completion. The explicit inclusion of a potential sale of the company signals real change-of-control optionality for the $1.2B-revenue chain, with advisor appointments or inbound interest leaks representing the next observable steps.
Featured in Issue #17 ·
Ziff Davis, Inc. ZD (US) · $45.07 · MCAP $1.7B · EV $1.7B
Fwd P/E: 8.8x · EV/EBITDA: 4.8x · EV/Sales: 1.4x · EV/GP: 2.0x (FY2026)
Ziff Davis operates as a digital media and internet company with a mix of digital media and subscription businesses in the US and internationally.
Ziff Davis (ZD) is conducting a broad strategic review to evaluate potential asset sales or spin-offs across its US and international digital media and subscription businesses. Management is working with advisors on the assessment, which was disclosed alongside recent soft financial results and negative organic growth driven by Google-related advertising and search headwinds. The review follows analyst estimate cuts and is described as the primary near-term catalyst to address current portfolio challenges. This board-initiated process opens the door to portfolio streamlining or a full break-up, and PMs should monitor for advisor appointments and any formal sale or spin-off process launch as the next concrete catalyst.
Featured in Issue #17 ·
Beeline Holdings, Inc. BLNE (US) · $1.18 · MCAP $11M · EV $36M
EV/Sales: 1.3x · EV/GP: 7.2x (FY2026)
Beeline Holdings, Inc. is a Nasdaq-listed Nevada corporation. The filing does not disclose its current operating business; the proposed counter-party TTYL is a blockchain-enabled platform focused on tokenizing deed-recorded fractional equity in U.S. residential real estate.
Beeline Holdings, Inc. (BLNE) formed a Special Committee of independent directors on May 15, 2026, to evaluate strategic opportunities including a potential transaction with TTYL. TTYL is a blockchain-enabled platform focused on tokenizing deed-recorded fractional equity in U.S. residential real estate. Any deal would represent a related-party transaction as Beeline CEO Nicholas R. Liuzza Jr. is the founder and principal shareholder of both companies. The strategic review process with a pre-identified target could signal a transformative reverse merger or asset injection into the public vehicle. No final decision has been made, and there is no assurance that a transaction will be entered into or consummated.
Featured in Issue #16 ·
Citius Oncology, Inc. CTOR (US) · $0.84 · MCAP $78M · EV $149M
EV/Sales: 7.1x (FY2026)
Citius Oncology is a Nasdaq-listed biopharmaceutical company commercializing LYMPHIR, a therapy for cutaneous T-cell lymphoma. It was spun out from Citius Pharmaceuticals in 2024.
Citius Oncology, Inc. (CTOR) is conducting an evaluation of strategic alternatives for the full company as disclosed in its May 15, 2026, 10-Q filing. The biopharmaceutical company’s auditor included an explanatory paragraph in the filing expressing substantial doubt about the entity's ability to continue as a going concern. As of March 31, 2026, the company reported $2.6M in cash and equivalents against current liabilities of $58.8M. Citius Oncology, which commercializes the cutaneous T-cell lymphoma therapy LYMPHIR, has a market capitalization below $70M and is currently working to regain compliance with Nasdaq continued listing requirements. This formal strategic review process could lead to a sale, merger, restructuring, or wind-down.
Featured in Issue #16 ·
GoPro, Inc. GPRO (US) · $1.00 · MCAP $171M · EV $257M
Fwd P/E: 20.0x · EV/Sales: 0.3x · EV/GP: 1.0x (FY2026)
GoPro designs and sells action cameras, accessories, and software that enable immersive content capture and sharing for consumers.
Gopro, Inc. (GPRO) retained Houlihan Lokey as financial advisor to evaluate a potential sale and other strategic alternatives following unsolicited inbound inquiries from the defense, consumer, and financial sectors. The strategic review is fully supported by CEO Nicholas Woodman and the Board to maximize shareholder value. Fenwick & West is serving as legal advisor to the company, which designs and sells action cameras, accessories, and software. No timetable for the process has been established, and there is no assurance that the evaluation will result in a transaction.
Featured in Issue #16 ·
Integer Holdings Corporation ITGR (US) · $89.28 · MCAP $3.0B · EV $4.1B
Fwd P/E: 14.7x · EV/EBITDA: 11.7x · EV/Sales: 2.3x · EV/GP: 9.8x (FY2026)
Integer Holdings operates in the medical technology and device sector, providing products and services that support healthcare manufacturers and related stakeholders.
Integer Holdings (ITGR) has enhanced change-of-control protections and retention packages for President and CEO Payman Khales and four senior executives. The board approvals on May 18 and May 20, 2026, are tied to an ongoing strategic review to maximize stockholder value. These protections signal board preparation for a potential transaction as the strategic review progresses. Shareholders also recently approved the 2026 Omnibus Incentive Plan, extending the equity award pool through 2036, and re-elected all 11 board directors. The company operates in the medical technology and device sector, providing products and services to healthcare manufacturers.
Featured in Issue #16 ·
Ensysce Biosciences, Inc. ENSC (US) · $0.32 · MCAP $3M · EV $2M
EV/Sales: 0.3x · EV/GP: 0.1x (LTM)
Ensysce Biosciences is a clinical-stage pharmaceutical company developing next-generation abuse-deterrent and overdose-protected opioid and stimulant therapies using its proprietary TAAP and MPAR platforms for severe pain, ADHD, and opioid use disorder.
Ensysce Biosciences (ENSC) has initiated a formal review of strategic alternatives to accelerate development of its proprietary TAAP and MPAR platforms. The review, announced with first quarter 2026 financial results, may include potential partnerships and licensing opportunities to unlock shareholder value. The clinical-stage pharmaceutical company reported $0.7M in cash as of March 31, 2026, and subsequently closed a $2.0M convertible preferred stock tranche in April 2026. Lead candidates include PF614 in Phase 3 and PF614-MPAR, which holds an FDA Breakthrough Therapy designation. This strategic review at a cash-constrained micro-cap could attract M&A interest or lead to a licensing deal.
Featured in Issue #16 ·
Wellgistics Health, Inc. WGRX (US) · $0.08 · MCAP $10M · EV $39M
Wellgistics Health, Inc. is a healthcare-focused company listed on the Nasdaq Capital Market, classified as an emerging growth company.
Wellgistics Health, Inc. (WGRX) withdrew its preliminary proxy statement on Schedule 14A filed on May 14, 2026, as the company continues to evaluate potential strategic transactions. No definitive proxy materials for the special stockholder meeting were distributed or mailed. The withdrawal indicates an active strategic review process potentially involving a sale, merger, or major recapitalization that could deliver a control premium to shareholders. Wellgistics Health, Inc. is a healthcare-focused emerging growth company listed on the Nasdaq Capital Market.
Featured in Issue #16 ·
Investcorp Credit Management BDC, Inc. ICMB (US)
Fwd P/E: 9.9x · EV/Sales: 34.7x · EV/GP: 34.7x (FY2026)
Investcorp Credit Management BDC is a business development company that invests primarily in first-lien debt of middle-market companies, with a portfolio fair value of approximately $151M across 34 borrowers.
Investcorp Credit Management BDC (ICMB) has formed a special committee of independent directors to evaluate strategic alternatives, retaining Houlihan Multicapital Inc. as financial adviser. Management confirmed the review on its Q1 2026 earnings call and declined to take questions, citing the ongoing process. The investment adviser voluntarily waived 56% of base management fees for the quarter, saving approximately $456,000, and the revolving credit facility commitment was reduced from $100M to $50M to save approximately $401,000 in annual undrawn fees. Investcorp Credit Management BDC is a business development company with a portfolio fair value of approximately $151M across 34 borrowers. The strategic alternatives review signals a potential sale, liquidation, or wind-down, creating a catalyst for price-to-NAV convergence.
Featured in Issue #16 ·
Hugoton Royalty Trust HGTXU (US) · $0.23 · MCAP $9M · EV $9M
Fwd P/E: 0.3x · EV/EBITDA: 0.1x · EV/Sales: 0.2x (LTM)
Hugoton Royalty Trust holds net profits interests in natural gas and oil properties in Kansas, Oklahoma, and Wyoming, collecting overriding royalties from working-interest owners XTO Energy and Mach Natural Resources.
Hugoton Royalty Trust (HGTXU) announced it will not declare a cash distribution for May 2026, with no distributions made since July 2023 due to accumulated excess costs. The Trustee expressed substantial doubt regarding the Trust's ability to continue as a going concern and has deferred its own fees since April 2024. On April 16, 2026, the Trust dismissed auditor Grant Thornton and will not seek a replacement or file its Q1 2026 10-Q due to cash constraints. A formal review of options is underway, including the possible termination of the Trust or the marketing of its net profits interests in Kansas, Oklahoma, and Wyoming. The Trustee expects a near-term resolution is unlikely, though the process represents a potential terminal event that could trigger a final distribution or wind-down for unitholders.
Featured in Issue #16 ·
Babcock & Wilcox Enterprises, Inc. BW (US) · $21.85 · MCAP $2.5B · EV $947M
Fwd P/E: NM · EV/EBITDA: 20.2x · EV/Sales: 1.0x · EV/GP: 4.1x (FY2026)
Babcock & Wilcox provides advanced energy and environmental technologies, including coal and gas-fired power generation, hydrogen production, carbon capture, and renewable energy solutions, with a vast installed base of over 400 GW globally.
Babcock & Wilcox Enterprises, Inc. (BW) is evaluating strategic alternatives for the company as disclosed in an investor presentation filed with the SEC. The review accompanies an obligation to refinance or repay 6.50% Notes due 2026 prior to their maturity. Forward-looking statements in the filing flag potential future conditions that could raise substantial doubt about the company's ability to continue as a going concern. B. Riley is disclosed as having significant influence over the company, which provides energy and environmental technologies including coal and gas-fired power generation, hydrogen production, carbon capture, and renewable energy solutions.
Featured in Issue #15 ·
BioAtla, Inc. BCAB (US) · $4.27 · MCAP $5M · EV $32M
EV/Sales: 1.6x · EV/GP: 1.6x (FY2026)
BioAtla is a clinical-stage biotechnology company developing conditionally active biologic (CAB) antibody therapeutics for solid tumors. Its lead candidates have completed Phase 2 trials, and the company is now operating with a sharply reduced R&D footprint.
BioAtla (BCAB) disclosed in its May 15, 2026, Form 10-Q that the board initiated a strategic review in March 2026 to evaluate options to maximize shareholder value. The company implemented an approximately 70% workforce reduction and expressed substantial doubt regarding its ability to continue as a going concern. As of March 31, 2026, cash and cash equivalents totaled $2.0M. A May 2026 license agreement amendment with Context Therapeutics is expected to provide $6.5M in non-recurring cash, and the company has access to a $15.0M standby equity purchase agreement with Yorkville. The review and restructuring at the clinical-stage biotechnology firm signal potential outcomes including a full-company sale, merger, or wind-down.
Featured in Issue #15 ·
BioXcel Therapeutics, Inc. BTAI (US) · $1.14 · MCAP $31M · EV $101M
BioXcel Therapeutics develops neuroscience medicines using an AI-driven drug re-innovation platform. Its lead asset, IGALMI (dexmedetomidine) sublingual film, is approved for in-care acute agitation and seeks label expansion into the at-home setting.
BioXcel Therapeutics (BTAI) has engaged MTS Health Partners as a financial advisor to evaluate strategic options including a potential sale, merger, collaboration, recapitalization, or continued standalone operation. The company, which develops neuroscience medicines using an AI-driven drug re-innovation platform, reported a first-quarter net loss of $12.7 million on product revenue of $206,000. As of March 31, 2026, the company held $17.2 million in cash and equivalents and remained in compliance with covenants under its Credit Agreement. The board-initiated review follows the FDA's acceptance of an sNDA for the at-home use of lead asset IGALMI, which has a PDUFA target action date of November 14, 2026. No decision has been made on any specific transaction, and no set timetable has been established for the process.
Featured in Issue #15 ·
Ensysce Biosciences ENSC (US) · $0.2801 · MCAP $3M
Ensysce Biosciences is a biopharmaceutical company developing novel small-molecule therapies with abuse-deterrent and overdose protection properties.
Ensysce Biosciences (ENSC) has launched a board-initiated formal review of strategic alternatives for the full company. The biopharmaceutical company, which develops novel small-molecule therapies with abuse-deterrent and overdose protection properties, disclosed the review in an 8-K filing. The process signals potential M&A, spin-off, or sale scenarios.
Featured in Issue #15 ·
Enviri Corporation NVRI (US) · $19.39 · MCAP $1.6B · EV $3.1B
EV/EBITDA: 18.1x · EV/Sales: 1.7x · EV/GP: 8.2x (FY2026)
Enviri Corporation provides environmental solutions and services, operating through Harsco Environmental, Clean Earth, and Rail segments, with a focus on materials processing, waste management, and industrial services.
Enviri Corporation (NVRI) reported Q1 revenue of $550M and adjusted EBITDA of $65M, with performance in the Harsco Environmental and Rail segments exceeding expectations. Management confirmed during the Q1 2026 earnings call that the dual-track strategic process involving the sale of the Clean Earth segment and the spin-off of New Enviri (whose Form 10 was declared effective Monday, May 11, 2026) is progressing as planned. The company reiterated its unchanged 2026 guidance and continues to focus on margin growth and risk reduction. The dual-track strategy is intended to unlock trapped value as the market re-rates the remaining stub and proceeds from the sale de-lever the balance sheet.
Featured in Issue #15 ·
Eos Energy Enterprises, Inc. EOSE (US) · $7.87 · MCAP $2.1B · EV $3.2B
EV/Sales: 10.5x (FY2026)
Eos Energy Enterprises develops and manufactures zinc-based long-duration energy storage systems for grid-scale applications.
Cerberus affiliates filed an amended Schedule 13D/A reporting a 32% beneficial stake in Eos Energy Enterprises (EOSE) and the signing of a binding term sheet to form a joint venture, Frontier Power USA Parent, LLC. Under the May 12, 2026 agreement, CCM Frontier will contribute $100M for 100M Class A-2 units and 50M Class A-1 units, gaining four of the seven initial board seats. Eos, which develops zinc-based long-duration energy storage systems, intends to fund its contribution to the venture via a $150M rights offering. The offering is planned at a 20% discount to a 15-day VWAP and will include warrants for participants. Cerberus-affiliated investors currently own approximately 159.6M of the 339.5M shares outstanding.
Featured in Issue #15 ·
Flag Ship Acquisition Corp FSHP (US) · $11.15 · MCAP $99M · EV $91M
Flag Ship Acquisition Corp operates as Forum Markets, focusing on digital asset markets, AI infrastructure financing, and real-world asset tokenization via its Liquidity.io platform.
Flag Ship Acquisition Corp (FSHP) has initiated a formal strategic review via a board special committee expected to remain active through the end of 2026. Since April, the company has repurchased approximately 5.8M shares for about $24.9M, retiring roughly 28% of its total shares outstanding. Management cited a valuation disconnect while lowering FY2026 revenue guidance to $18M-$22M and AUM guidance to $100M-$175M. For Q1 2026, the company recorded a $77.5M net loss on revenue of approximately $2.9M, an increase from $2.4M in Q4 2025. Flag Ship Acquisition Corp is shifting its focus toward AI infrastructure financing and real-world asset tokenization via its Liquidity.io platform. The board-initiated review at a company that has already retired 28% of its float signals potential for a full sale, take-private, or transformative transaction.
Featured in Issue #15 ·
GoPro, Inc. GPRO (US) · $1.11 · MCAP $190M · EV $257M
Fwd P/E: 22.2x · EV/Sales: 0.3x · EV/GP: 1.0x (FY2026)
GoPro designs and sells action cameras and accessories known for rugged, immersive video capture, popular with surfers, skiers, and adventure-sports enthusiasts. The company also offers a subscription service but remains primarily a hardware business.
GoPro (GPRO) is exploring strategic alternatives, including a possible sale or merger, after receiving unsolicited interest. Houlihan Lokey is advising on the review process. The manufacturer of action cameras and accessories currently has a market capitalization of approximately $187 million with shares trading near $1, down from a 2014 peak of $12 billion. Founder Nick Woodman holds a 16.5% stake and controls more than 50% of the voting power through Class B shares. The strategic review follows an April 2026 restructuring that included cutting approximately 145 employees, or 23% of the workforce.
Featured in Issue #15 ·
Hain Celestial HAIN (US) · $0.7779 · MCAP $70M · EV $862M
Fwd P/E: 9.4x · EV/EBITDA: 16.2x · EV/Sales: 0.7x · EV/GP: 3.5x (FY2027)
Hain Celestial is a natural and organic food company with products sold in over 75 countries, spanning snacks, teas, and baby food. The company generated $1.45B in revenue over the trailing twelve months.
Hain Celestial (HAIN) CEO Alison Lewis confirmed its full-company strategic review with Goldman Sachs is making "good progress." The natural and organic food company reported Q1 CY2026 revenue of $338.4 million, down 13.3% year-over-year and 3% below analyst estimates, while adjusted EPS of -$0.01 was in line with consensus. Hain recently completed its North American snacks divestiture to enhance its margin and cash flow profile. The company maintains a market capitalization of approximately $60 million and generated $1.45 billion in revenue over the trailing twelve months. An ongoing strategic review with a named advisor at a micro-cap consumer staples company often leads to a full-company sale, merger, or breakup.
Featured in Issue #15 ·
Integer Holdings Corporation ITGR (US) · $88.16 · MCAP $3.0B · EV $4.1B
Fwd P/E: 14.5x · EV/EBITDA: 11.7x · EV/Sales: 2.3x · EV/GP: 9.8x (FY2026)
Integer Holdings Corporation is a contract manufacturing organization serving the medical device industry, producing components and assemblies for cardiac, neuromodulation, and vascular applications.
Integer Holdings Corporation (ITGR) has initiated a strategic review of the full company, prompting Oppenheimer to upgrade the stock to Outperform from Perform with a $115 price target. The medical device contract manufacturing organization reported Q1 2026 EPS of $1.20 on revenue of $440 million, surpassing estimates, but revised its full-year 2026 guidance downward. Oppenheimer cited the board-initiated review and a favorable risk-reward profile for the upgrade, noting private equity interest within the contract manufacturing sector. The stock is currently trading at $84.98, having recovered only slightly from a year-end 2025 sell-off prior to the announcement. The strategic review process creates a potential pathway to a sale or take-private transaction.
Featured in Issue #15 ·
Investcorp Credit Management BDC, Inc. ICMB (US) · $1.43 · MCAP $21M · EV $165M
Fwd P/E: 10.2x (FY2026)
Investcorp Credit Management BDC, Inc. is a business development company that provides debt and equity financing to middle-market companies.
Investcorp Credit Management BDC, Inc. (ICMB) disclosed during its Q1 2026 earnings call that it is reviewing strategic alternatives for the company. The announcement coincided with a 14% sequential decline in net assets resulting from portfolio fair value declines. Management has implemented cost-saving measures including a fee waiver and a credit facility amendment while maintaining a focus on capital preservation. The strategic review alongside declining net asset value signals the potential for a restructuring, sale, or wind-down of the BDC.
Featured in Issue #15 ·
Neuphoria Therapeutics Inc. NEUP (US) · $4.73 · MCAP $25M · EV $-10M
Neuphoria Therapeutics is a clinical-stage biotech that was developing BNC210 for social anxiety disorder and PTSD. The lead program has now failed Phase 3, and the company has no revenue-generating products.
Neuphoria Therapeutics Inc. (NEUP) has initiated a review of strategic alternatives, including potential mergers, partnerships, or licensing transactions, following the Phase 3 failure of its lead asset BNC210. The AFFIRM-1 trial in social anxiety disorder failed primary and secondary endpoints, leading the company to pause all research and development and terminate most staff. According to its May 15, 2026, 10-Q filing, the board is working with advisors while the company records restructuring charges and concludes the employment of its CEO. Revenue for the third quarter of 2026 fell to $0 from $15 million in the prior-year period due to the absence of milestone payments from Merck. Neuphoria Therapeutics reported a third-quarter EPS of $(0.09).
Featured in Issue #15 ·
Orion Office REIT ONL (US) · $2.90 · MCAP $165M · EV $587M
EV/EBITDA: 35.3x · EV/Sales: 4.2x · EV/GP: 7.5x (FY2026)
Orion Office REIT acquires, owns, and manages a diversified portfolio of Class A office properties across U.S. markets, focusing on suburban single-tenant assets and transitioning toward dedicated use properties like medical and R&D facilities. It was spun off from Government Properties Income Trust in June 2021.
Orion Office REIT (ONL) is conducting a board-initiated strategic alternatives review with advisors Wells Fargo and JPMorgan. During its Q1 earnings call, the company disclosed approximately $100,000 in legal expenses related to the review and activist shareholder relations. Orion reaffirmed its 2026 Core FFO guidance of $0.69-$0.76 and declared a $0.02/share quarterly dividend. The company expects to apply nearly all $46 million in proceeds from three pending property sales to debt reduction. Management stated the review is progressing well but provided no specifics or timing. Orion, which manages a portfolio of Class A suburban single-tenant office properties, was spun off from Government Properties Income Trust in June 2021.
Featured in Issue #15 ·
Seritage Growth Properties SRG (US) · $2.41 · MCAP $136M · EV $183M
EV/Sales: 0.9x · EV/GP: 9.7x (FY2027)
Seritage Growth Properties is a national owner and developer of retail, residential, and mixed-use properties, originally formed from a Sears lease portfolio. The company is in wind-down mode, monetizing assets under a shareholder-approved plan, with a remaining portfolio of 10 properties across 0.8M square feet and 154 acres of land.
Seritage Growth Properties (SRG), originally formed from a Sears lease portfolio, is conducting a strategic review including a potential sale of the entire company while executing its 2022 asset monetization plan. In Q1 2026 results, the company issued a going-concern warning, noting its $63.2M cash balance as of May 14, 2026, which includes restricted cash, is insufficient to fund obligations including a $50M term loan maturing July 31, 2026. The Q1 2026 net loss widened to $(31.3)M, or $(0.56) per share, and the company reported $15.2M in impairment charges. No assets are currently under contract with closings deemed probable, and the remaining portfolio consists of 10 properties totaling 0.8M square feet and 154 acres. Securities class action and derivative lawsuits remain stayed pending a motion to dismiss in the Southern District of New York.
Featured in Issue #15 ·
SUNation Energy Inc. SUNE (US) · $1.65 · MCAP $6M · EV $5M
SUNation Energy provides residential and commercial solar energy installation services through two operating segments: SUNation NY serving New York and Hawaii Energy Connection (HEC) serving Hawaii.
SUNation Energy (SUNE) has initiated a formal strategic review to evaluate a potential sale, merger, asset sales, or other transactions. The board launched the process in April 2026 as management issued a going-concern warning following a Q1 2026 revenue decline to $7.2M from $12.6M YoY. The company reported a $4.1M net loss for the period and $5.2M in operating cash outflows, which reduced cash on hand to $1.7M. SUNation retained Maxim Group LLC as an advisor and entered a $3.6M at-the-market equity offering agreement for incremental financing. Recent liquidity actions include expanding a related-party revolver to $1.5M and converting $1.2M of related-party debt into 677,966 common shares.
Featured in Issue #15 ·
The Glimpse Group, Inc. GGRP (US) · $0.6493 · MCAP $14M · EV $14M
Fwd P/E: 8.1x · EV/Sales: 0.8x · EV/GP: 1.2x (FY2027)
The Glimpse Group (NASDAQ: GGRP) is a diversified Immersive Technology platform whose Brightline Interactive subsidiary provides advanced Physical AI infrastructure software and services, primarily to the U.S. Department of War and big-data enterprises via its SpatialCore platform.
Glimpse Group, Inc. (GGRP) is executing a strategic pivot to refocus exclusively on its Brightline Interactive (BLI) subsidiary as a pureplay Physical AI company serving the U.S. Department of War and big-data enterprises. The company will evaluate strategic alternatives for Glimpse Learning, shut down S5D, and has withdrawn its previously announced BLI IPO process. A group including the company's two largest investors and incoming board members invested approximately $1.85 million at $0.55/share with 125% warrant coverage. Around June 1, a new board including Retired Admiral Scott Swift as Chairman, Retired Major General Pete Fesler, and former Citigroup MD Brian Archer will replace the current board. CEO Lyron Bentovim will be replaced by BLI General Manager Tyler Gates as part of the transition. This board-initiated reorganization signals a potential value-unlocking catalyst amid the disposal of legacy assets and the aborted IPO.
Featured in Issue #15 ·
Tucows Inc. TCX (US) · $14.64 · MCAP $163M · EV $883M
EV/EBITDA: 11.9x · EV/Sales: 1.8x · EV/GP: 7.7x (FY2026)
Ting Internet is a fiber-optic internet service provider offering gigabit broadband to residential and business customers in select U.S. markets, operating as a segment of Tucows Inc.
Tucows (TCX) announced a strategic review of its Ting Internet segment during its Q1 2026 earnings on May 11. CEO David Woroch identified the process as a top priority and stated the company is actively working toward an outcome, which could include a sale, spin-off, or restructuring of the fiber-optic provider. Ting Internet added 2,900 subscribers in Q1 2026 to reach a total of 56,800, with segment revenue rising 19% year-over-year to $19.4 million. A separation or monetization could unlock value for shareholders as the segment shows growth but may be undervalued within the parent company.
Featured in Issue #15 ·
Canada 15 situations
FRNT Financial Inc. FRNT.V (CA) · MCAP $3M · EV $2M
FRNT Financial Inc. is a Canadian financial services company listed on the TSX Venture Exchange, with cross-listings on the OTCQB and Frankfurt Stock Exchange.
FRNT Financial Inc. (FRNT.V) provided an update on its previously announced strategic alternatives review alongside operational cost reduction progress reported for Q3 fiscal 2026. The Canadian financial services company maintains listings on the TSX Venture Exchange, OTCQB, and Frankfurt Stock Exchange. There is currently no definitive agreement or firm offer in place. This combination of a review update and cost reduction progress suggests the company is streamlining operations to present a cleaner asset to potential acquirers or merger partners, with the next catalyst being a definitive agreement or the termination of the review process.
Featured in Issue #18 ·
Pacific Booker Minerals Inc. BKM.V (CA) · MCAP $36M · EV $36M
Pacific Booker Minerals owns the Morrison copper-gold-molybdenum porphyry project in central British Columbia, a large-scale undeveloped deposit supported by a 2009 feasibility study.
Pacific Booker Minerals Inc. (BKM.V) is conducting a strategic review overseen by a special committee following an unsolicited bid from American Eagle Gold Corp. INFOR Financial delivered an independent fairness opinion finding the hostile offer financially inadequate, and the board recommends that shareholders do not tender. RCI Capital Group is managing a structured outreach process involving a technical dataroom and meetings with interested counterparties. Tetra Tech is performing a technical review of the Morrison Project with updated capex, opex, and metal price assumptions. The company also established a Technical Advisory Board chaired by Leo Hathaway to strengthen technical oversight. The mid-June 2026 technical assessment may set a floor valuation that either forces American Eagle to bump its offer or attracts a white-knight bidder.
Featured in Issue #18 ·
Doubleview Gold Corp. DBG.V (CA) · MCAP $420M · EV $414M
Doubleview Gold Corp. is a Vancouver-based mineral resource exploration and development company focused on precious and base metal projects in British Columbia, Canada. Its flagship asset is the Hat Project, a polymetallic copper-gold-cobalt-scandium porphyry deposit in BC's Golden Triangle.
Doubleview Gold Corp. (DBG.V) initiated a formal strategic review on June 2, 2026, focused on a potential sale of the company or its Hat Project flagship asset. Canaccord Genuity Corp. was appointed as financial advisor to evaluate transactions including mergers, joint ventures, recapitalizations, and strategic investments from sovereign wealth funds or government-backed entities. Preliminary Economic Assessment figures for the Hat Project show an after-tax NPV(5%) of C$6.73B to C$14.85B and an IRR ranging from 19% to 39%. No defined timetable for completion has been established. The central special-situations hook is the wide valuation gap between the junior mining explorer’s market capitalization and the C$6.7B+ net present value of its primary critical-minerals asset.
Featured in Issue #18 ·
Pacific Booker Minerals Inc. PBMLF (CA) · $1.67 · MCAP $28M · EV $10M
Pacific Booker Minerals is a Canadian junior resource company holding the wholly-owned Morrison Project, a copper-gold-molybdenum deposit in central British Columbia. The project is at the pre-feasibility stage, and the company is currently evaluating strategic alternatives for the asset.
Pacific Booker Minerals Inc. (PBMLF) engaged Tetra Tech Canada Inc. to perform a technical review and conceptual economic assessment of its wholly-owned Morrison Project in central British Columbia. The four-week engagement is intended to support the company's ongoing strategic review and facilitate technical evaluation by potential strategic parties. The scope of work for the copper-gold-molybdenum deposit is limited to a high-level review of historical data and does not include new exploration or resource estimation. This engagement signals a shift from internal review to active data-room preparation for the asset. The hiring of an engineering consultant for data-room preparation marks a tangible step forward in the strategic alternatives process for the long-dormant project, with the completion of the report in approximately four weeks expected to position the company to formally solicit bids or partnership proposals.
Featured in Issue #17 ·
Largo Inc. LGO.TO (CA) · MCAP $70M · EV $58M
EV/EBITDA: 22.9x · EV/Sales: 0.5x (FY2026)
Largo Inc. is the world's largest primary vanadium producer, operating the Maracás Menchen Mine in Brazil. The company's non-core portfolio includes two large, undeveloped tungsten-molybdenum deposits in Canada and Brazil.
Largo Inc. (LGO) launched a strategic review of its 100%-owned tungsten assets, including the Northern Dancer project in Yukon, Canada, and the Currais Novos project in Brazil. The review follows the receipt of unsolicited expressions of interest and will evaluate asset-level transactions such as partnerships, joint ventures, minority investments, a sale, or a spin-out. Management intends to engage a financial advisor to manage the process for these undeveloped tungsten-molybdenum deposits, which are currently considered non-core to the company's primary vanadium operations. No definitive timetable has been set for the review, and there is no assurance it will result in a transaction. A sale or spin-out could surface a value catalyst for shares currently anchored to core vanadium operations, with unsolicited interest suggesting the process has a running start.
Featured in Issue #17 ·
Pacific Booker Minerals Inc. BKM.V (CA) · MCAP $28M · EV $7M
Pacific Booker Minerals is a Canadian junior mining company advancing its wholly-owned Morrison Project, a copper-gold-molybdenum porphyry deposit in central British Columbia.
Pacific Booker Minerals (BKM.V) engaged Tetra Tech Canada Inc. to conduct a 4-week review of historical data and prepare a conceptual economic assessment for the Morrison Project in central British Columbia. The engagement supports an ongoing strategic review process intended to facilitate evaluation of the wholly-owned copper-gold-molybdenum porphyry deposit by potential strategic parties. This high-level review excludes new exploration, resource estimation, and mine planning, though results may form the basis for a future Preliminary Economic Assessment. The advisor engagement signals the board is actively preparing the asset for potential partners.
Featured in Issue #16 ·
Kneat.com KSI.TO (CA) · MCAP $355M · EV $328M
EV/EBITDA: 12.8x · EV/Sales: 5.8x · EV/GP: 10.6x (FY2026)
Kneat.com provides a healthcare software-as-a-service (SaaS) platform focused on mission-critical validation and compliance processes for life sciences companies.
Kneat.com (KSI.TO) is undergoing a formal strategic review exploring a sale of its full company, a process initiated in February and disclosed in its Q1 results. Stifel raised its price target for the provider of healthcare software-as-a-service validation and compliance platforms to $5.75 from $5.50, noting the review highlights potential private-market interest. The company reported Q1 revenue of $18.0M and annual recurring revenue of $76.4M, representing year-over-year increases of 22.1% and 20.3% respectively. Kneat.com ended the quarter with $51.1M in cash and $31.1M in net cash.
Featured in Issue #16 ·
CAE Inc. CAE.TO (CA) · MCAP $7.5B · EV $10.4B
Fwd P/E: 25.8x · EV/EBITDA: 10.4x · EV/Sales: 2.9x · EV/GP: 10.7x (FY2027)
CAE is a Montreal-based manufacturer of high-fidelity flight simulators and provider of aviation training services. Its Flightscape division offers cloud-native airline operations software covering flight planning, crew management, and disruption recovery.
CAE (CAE.TO) has initiated a formal strategic review of its Flightscape cloud-native aviation software division, exploring a potential sale, partnership, or minority investment. The segment-level review is part of a transformation plan led by CEO Matthew Bromberg to refocus the company on its core flight simulation and training businesses. Flightscape was established through a $392.5M acquisition of Sabre's AirCentre portfolio in 2022 and currently employs more than 600 professionals. Concurrent efficiency measures include a 2% reduction in CAE's workforce and a 10% cut in commercial full-flight simulators. A divestiture of the SaaS division could reshape the company's capital allocation and impact airline software licensing and support models.
Featured in Issue #16 ·
Dye & Durham Limited DND.TO (CA) · MCAP $146M · EV $1.1B
EV/EBITDA: 19.6x · EV/Sales: 5.7x · EV/GP: 17.3x (FY2027)
Dye & Durham provides cloud-based workflow software and information services for legal professionals, financial institutions, and businesses. The company aggregates public records and registry data, embedding it into applications used for property searches, corporate filings, and compliance, with operations in Canada, the UK, and Australia.
Dye & Durham (DND.TO) is conducting a full-company strategic review aimed at portfolio streamlining and leverage reduction. The process follows the completion of key debt refinancing steps in early 2026. The company provides cloud-based workflow software and information services for legal professionals in Canada, the UK, and Australia. The review could result in material portfolio simplification, asset divestitures, or a full-company sale. The stock has seen elevated volatility and remains under close watch by North American investors following the refinancing activity.
Featured in Issue #16 ·
Slate Grocery REIT SGR.UN.TO (CA) · MCAP $683M · EV $2.2B
Fwd P/E: 706.7x · EV/EBITDA: 19.4x · EV/Sales: 12.1x (LTM)
Slate Grocery REIT owns and operates a $2.4 billion portfolio of 115 grocery-anchored retail properties across 23 US states, with tenants including Kroger, Walmart, and Publix.
Slate Grocery REIT (L) has formed an independent special committee to evaluate strategic alternatives, including a potential sale of the full company. The board-initiated review follows the receipt of an unsolicited proposal from affiliates of Slate Asset Management, the REIT’s external manager. Evercore has been retained as exclusive financial advisor and Raider Hill Advisors as exclusive real estate advisor for the process. Slate Grocery REIT owns and operates a $2.4 billion portfolio of 115 grocery-anchored retail properties across 23 US states. The formal solicitation of third-party bids provides a catalyst for price discovery as the REIT evaluates the proposal. No assurance has been given that the review will result in a transaction.
Featured in Issue #16 ·
American Hotel Income Properties REIT LP HOT-UN.TO (CA) · MCAP $42M · EV $174M
EV/EBITDA: 13.2x · EV/Sales: 1.3x · EV/GP: NM (FY2026)
American Hotel Income Properties REIT LP is a real estate investment trust that owns a portfolio of hotel properties, generating revenue primarily from room bookings and related hospitality services.
American Hotel Income Properties REIT LP (HOT-UN.TO) is conducting an ongoing strategic review alongside a program of active asset divestitures. Q1 2026 revenue declined 25.2% year-over-year due to prior hotel sales, though same-property ADR and RevPAR improved modestly. The company plans further hotel sales to enhance liquidity and reduce debt, with no major debt maturities scheduled until late 2026. The combination of the strategic review and disposals suggests a potential full-company sale, merger, or privatization is in play.
Featured in Issue #15 ·
CAE Inc. CAE.TO (CA) · MCAP $8.2B · EV $10.5B
Fwd P/E: 28.5x · EV/EBITDA: 12.0x · EV/Sales: 3.0x · EV/GP: 10.7x (FY2027)
CAE Inc. is a provider of mission-critical simulation and training for civil aviation and defense, supported by a large installed base and long-term contracts.
CAE Inc. (CAE.TO) announced on 11 May 2026 that it is exploring strategic alternatives for Flightscape, its standalone aviation software business, as part of a portfolio optimization review. Alternatives for the cloud-native SaaS platform include partnerships, minority or majority investments, or a full sale. The review could lead to a divestiture that reshapes the company's mix between capital-intensive hardware and higher-growth software. CAE Inc. is a provider of mission-critical simulation and training for civil aviation and defense supported by a large installed base and long-term contracts.
Featured in Issue #15 ·
FRNT Financial Inc. FRNT.V (CA) · MCAP $4M · EV $12M
FRNT Financial is a Toronto-based digital asset investment bank providing capital markets and advisory services to institutional investors. It offers trading, structured derivatives, merchant banking, and lending origination bridging traditional and crypto finance.
FRNT Financial (FRNT.V) has initiated a formal review of strategic alternatives and engaged Joseph Gunnar & Co., LLC as its financial advisor. The board-led process follows multiple unsolicited approaches received over the past nine months, none of which were consummated. Considered alternatives include a merger or acquisition, divestitures, a going-private transaction, an uplisting, or continued standalone execution. FRNT Financial, a Toronto-based digital asset investment bank, has not set a definitive timetable for the review and will not provide further updates until a specific transaction is approved. The process signals a potential catalyst for M&A, an uplisting, or a take-private transaction.
Featured in Issue #15 ·
Mercer International Inc. MERC (CA) · $0.9400 · MCAP $63M · EV $1.6B
EV/EBITDA: 7.6x · EV/Sales: 0.8x (FY2026)
Mercer International is a global forest products company producing market pulp and solid wood products, with manufacturing operations in Germany and Canada.
Mercer International (MERC) has formed a special committee to evaluate strategic alternatives focused on financing and liquidity. CFO Richard Short disclosed the review on the Q1 2026 earnings call, citing the evaluation of strategic and financing options. The review signals a need for transformative financing and could lead to asset sales, capital raises, or a full company sale. For Q1 2026, the forest products company reported operating EBITDA of approximately $8 million, representing a $28 million sequential increase from Q4 2025. Mercer also outlined a $60 million to $80 million capital expenditure plan for 2026.
Featured in Issue #15 ·
Sangoma Technologies Corp SANG (CA) · $3.64 · MCAP $121M · EV $245M
EV/EBITDA: 17.4x · EV/Sales: 1.2x · EV/GP: 2.3x (FY2027)
Sangoma Technologies provides unified communications (UCaaS) and communications platform (CPaaS) solutions, including voice infrastructure, SIP trunking, and managed services, primarily to small and mid-sized customers.
Sangoma Technologies (SANG) initiated a strategic review to consider options for unlocking shareholder value following Q3 results that missed consensus on revenue, gross margins, and EBITDA. The company reduced its FY2026 guidance as LTM revenue declined 8.9% year-over-year to $219.7M, driven by UCaaS and CPaaS pricing pressure for small and mid-sized customers. Canaccord downgraded the stock to Hold from Speculative Buy and halved its price target to $4.00 from $9.00. Sangoma Technologies reported Q3 free cash flow of $0.11 per share, and the stock closed at $3.66, down 36% over the past year. The board-led review serves as a catalyst for potential M&A, take-private transactions, or asset sales with shares trading near multi-year lows.
Featured in Issue #15 ·
Australia 12 situations
Findi Limited FND.AX (AU) · MCAP $34M · EV $116M
Findi Limited is an ASX-listed digital payments and financial services provider operating in India through its subsidiary Transaction Solutions International (TSI). The group's three business units span payment infrastructure and financial services, with a strategic focus on securing an Indian Payments Bank licence.
Findi Limited (FND.AX) has commenced a strategic review of its three operating business units and engaged external advisers to optimize capital allocation and identify synergies. The review aims to formalize a pathway toward securing a Payments Bank license in India and progressing a planned IPO of the subsidiary Transaction Solutions International (TSI). Concurrent with the 5 June 2026 announcement, Stephen Benton was appointed Non-Executive Chairman, while Nicholas Smedley shifted focus to the execution of the India-based IPO. The board expects to complete the review over the next few months. This board-initiated review signals a concrete catalyst to unlock value via the separation or IPO of the Indian subsidiary and progress on a banking license, placing the early-stage process on the watchlist for potential structure trades.
Featured in Issue #18 ·
Energy World Corporation Ltd EWC.AX (AU) · MCAP $198M · EV $208M
Energy World Corporation develops and operates power generation and energy infrastructure assets, with a focus on LNG-based power projects in the Asia-Pacific region.
Energy World Corporation Ltd (EWC.AX) requested an immediate ASX trading halt on May 31, 2026, to finalize a material update regarding its ongoing strategic review. The developer of LNG-based power generation and energy infrastructure expects the halt to remain in effect until the release of the update or the resumption of normal trading on June 3, 2026. The company maintains a market capitalization of $198M and an enterprise value of $208M following a -37.93% year-to-date share price decline. This trading halt forces a binary catalyst by June 3, at which point the update will reveal whether the review concludes with a control transaction, asset sale, or status quo continuation.
Featured in Issue #18 ·
nib Group NHF.AX (AU) · MCAP $2.3B · EV $2.3B
Fwd P/E: 14.1x (FY2027)
nib Group is a listed Australian private health insurer, also providing related health services. The travel insurance operations being divested included World Nomads, Travel Insurance Direct (TID), and nib Travel branded products.
nib holdings limited (NHF.AX) concluded its May 2025 strategic review of nib Travel by signing a definitive agreement to sell its Australia and New Zealand travel insurance portfolio to Allianz Partners for $35M. The transaction, supported by advisors Jarden and Ashurst, follows the February 2026 sale of the World Nomads brand to SiriusPoint for A$67.5 million and includes a long-term distribution agreement to generate ongoing commissions for nib. For FY25, the consolidated travel operations contributed A$6.7 million to the group’s A$239.2 million underlying operating profit. This completion of the full exit from travel insurance triggers a capital management review of the approximately A$117.5 million in combined proceeds, creating a potential return-of-capital catalyst via a special dividend or buyback.
Featured in Issue #18 ·
Treasury Wine Estates Ltd TWE.AX (AU) · MCAP $2.7B · EV $3.9B
Fwd P/E: 14.1x · EV/EBITDA: 9.1x · EV/Sales: 2.3x · EV/GP: 5.0x (FY2027)
Treasury Wine Estates Limited (TWE.AX), an Australian-based global wine company with a $2.7B market capitalization, announced a strategic review of its Americas division on June 4, 2026. The owner of the luxury Penfolds brand and American labels Daou and Beringer plans to slash its brand portfolio as part of the segment-level review. Currently in the strategic phase, the process has a medium-term catalyst timeline. This review serves as a catalyst for the company’s Americas business and brand portfolio.
Featured in Issue #18 ·
Dexus DXS.AX (AU) · MCAP $4.2B · EV $7.4B
Fwd P/E: 9.2x · EV/EBITDA: NM · EV/Sales: 12.5x · EV/GP: 16.4x (FY2027)
Dexus is an ASX-listed fully integrated real asset group managing a A$51.5B portfolio of office, industrial, retail, healthcare, and infrastructure investments, including A$36.2B in third-party funds management.
Dexus (DXS.AX) has initiated a strategic review of its $7.3B infrastructure funds and mandates business, which accounts for approximately 20% of third-party funds under management and $35M in annual management fees. The review encompasses the DDIT, CommIF, DCIF, and APAFs vehicles after the company stood down key executives and dismissed financial advisors previously appointed for the APAC sale process. Concurrently, the New South Wales Supreme Court extended an injunction related to the APAC litigation until June 22, 2026, to allow Dexus Bloc shareholders time to negotiate undertakings or pursue appeals. An update on the review is expected by the August 2026 results briefing. A potential restructuring or exit from the infrastructure segment acquired from AMP Capital in 2023 creates a near-term catalyst for the name.
Featured in Issue #18 ·
Infragreen IFN.AX (AU) · MCAP $74M · EV $69M
Fwd P/E: 13.5x · EV/EBITDA: 10.8x
Infragreen builds and operates sustainable mid-market infrastructure businesses across Australia and New Zealand, focusing on regulated waste, resource recovery, and industrial services.
Infragreen (IFN.AX) concluded its strategic review with advisers Grant Samuel and Talbot Sayer, following an assessment that the current share price materially undervalues the business. The board authorized a $10 million on-market share buyback commencing June 12, 2026, and confirmed that a sale process for portfolio company Pure Environmental is currently underway. An independent portfolio valuation has been commissioned and is expected within six weeks. Enhanced business-level financial disclosure will also begin with H1 FY27 results. The review concludes without a whole-company sale, using the buyback and potential divestments to narrow the perceived discount while the independent valuation arriving in approximately six weeks provides a near-term NAV benchmark.
Featured in Issue #17 ·
OFX Group Limited OFX.AX (AU) · MCAP $95M · EV $78M
Fwd P/E: 36.8x
OFX Group provides online international payment and foreign exchange services to businesses and consumers globally.
OFX Group (OFX.AX) is undergoing a board-initiated strategic review of the full company considering organic and inorganic options to maximize shareholder value. An outcome from the process is expected before June 30, 2026. The review follows FY26 results showing an 8.5% year-over-year decline in Net Operating Income to $196.6 million and a 56.4% drop in Underlying EBITDA to $25.2 million. Over 90% of corporate clients have migrated to the new OFX 2.0 platform, while non-FX revenue increased 12.1%. The company targets a return to growth in FY27 with 15%+ NOI growth and an approximately 30% medium-term EBITDA margin.
Featured in Issue #16 ·
Healius Ltd HLS.AX (AU) · MCAP $186M · EV $718M
EV/EBITDA: 9.1x · EV/Sales: 0.7x · EV/GP: 2.4x (FY2027)
Healius operates one of Australia's largest networks of pathology laboratories, collection centers, and diagnostic imaging sites, providing routine and specialist testing as well as radiology services. Its revenue is driven by pathology testing volumes and diagnostic imaging under the Lumus brand, supported by government rebates and private insurers.
Healius Ltd (HLS.AX) commenced a strategic review of its Lumus diagnostic imaging business following a May 2026 trading update in which the company lowered its FY2026 earnings guidance. The Lumus segment contributes a meaningful share of group revenue through radiology and imaging services, and the review follows a period of pathology operational challenges and share price volatility. The strategic review of this material segment signals potential divestiture or restructuring to facilitate value realization or a simplification of the corporate structure.
Featured in Issue #16 ·
Besra Gold Inc BEZ.AX (AU) · MCAP $34M · EV $3M
Besra Gold is an ASX-listed junior gold developer focused on advancing its core Bau Gold Project in Sarawak, Malaysia. The Company has been conducting a strategic review since July 2025 to evaluate pathways for the project.
Besra Gold (BEZ.AX) appointed Dr. Raymond Shaw as Executive Director and CEO effective 11 May 2026, a move explicitly tied to a strategic review initiated in July 2025. Shaw, who previously served as the junior gold developer’s Chief Technical Officer, will receive a base salary of A$270,000 p.a. The ongoing review focuses on advancing the Bau Gold Project in Sarawak, Malaysia, though no specific outcomes, financing, or timelines have been disclosed. The appointment reinforces a process that could lead to a financing, joint venture, or corporate transaction for the company's core asset.
Featured in Issue #15 ·
CSL Limited CSL.AX (AU) · MCAP $41.6B · EV $61.2B
Fwd P/E: 16.5x · EV/EBITDA: 18.5x · EV/Sales: 6.0x · EV/GP: 11.7x (FY2027)
CSL Limited researches, develops, manufactures, and distributes biopharmaceutical products and vaccines globally, with operations spanning Australia, the US, Germany, the UK, Switzerland, China, and Hong Kong.
CSL Limited (CSL.AX) is planning a demerger of its CSL Seqirus influenza vaccine business by the end of FY2026. The biopharmaceutical company recently completed an on-market buyback and cancelled approximately 6.4 million ordinary shares. This portfolio separation is accompanied by a CEO transition and flagged restructuring costs that may pressure near-term margins. Analyst estimates project revenue of $17.8B and earnings of $3.7B by 2029 for the entity. While reshaping the company's investment narrative, the demerger introduces execution risk and forecast uncertainty regarding future capital allocation.
Featured in Issue #15 ·
Healius HLS.AX (AU) · MCAP $195M · EV $721M
EV/EBITDA: 9.1x · EV/Sales: 0.7x · EV/GP: 2.4x (FY2027)
Healius is a major Australian healthcare company operating pathology and diagnostic imaging services, as well as the Agilex Biolabs contract research unit.
Healius (HLS.AX) has commenced a comprehensive strategic review of its assets, creating potential for divestiture, spin-off, or portfolio simplification catalysts. The company narrowed its FY26 group underlying EBITDA guidance to $259M–$264M and EBIT to $30M–$35M. Within its divisions, pathology revenue grew 2.4% despite a 0.4% volume decline in the ten months to April 2026, while the Agilex Biolabs unit recorded year-to-date revenue growth of 13.7%. Pathology labour costs are projected to increase by $1.8M in Q4 FY26 following a Fair Work Commission gender-based undervaluation ruling.
Featured in Issue #15 ·
Kingsgate Consolidated Limited KCN.AX (AU) · MCAP $1.1B · EV $499M
Fwd P/E: 5.2x · EV/EBITDA: 1.7x · EV/Sales: 0.9x · EV/GP: 4.2x (FY2027)
Kingsgate Consolidated is an Australian gold and silver mining and development company. It operates the Chatree Gold Mine in Thailand and is advancing the Nueva Esperanza Silver-Gold Project in Chile's Atacama region.
Kingsgate Consolidated (KCN.AX) entered definitive agreements with Inversiones Anglo American Norte SpA to acquire royalty and water rights at the Nueva Esperanza project for US$21.6M. The transaction involves US$15.6M cash and US$6.0M in contingent payments, funded via A$139M in existing cash reserves and a US$15M undrawn credit facility. The buyout eliminates US$2.0M per year in pre-production royalties, removes 5% and 3% NSR royalties, and settles US$8.1M in unpaid royalties. Kingsgate is concurrently conducting a strategic review to evaluate value realization pathways for the project, including a potential separate ASX listing. Targeted technical work is being accelerated, with a metallurgical drill program starting within six weeks and water infrastructure construction expected imminently.
Featured in Issue #15 ·
Sweden 6 situations
Diamyd Medical AB DMYD-B.ST (SE) · MCAP $16M · EV -$4M
Diamyd Medical AB is a Swedish diabetes research company developing the Diamyd vaccine (GAD-based) for type 1 diabetes. It also holds a GMP-certified manufacturing facility in Umeå.
Diamyd Medical AB ser. B (DMYD-B.ST) has disclosed that its ongoing strategic review has yielded multiple formal non-binding letters of intent and investment proposals from external parties. The review follows the termination of a Phase 3 study for the retogatein drug candidate and the April appointment of Chairman Anders Essen-Möller as CEO. Key assets under evaluation include the retogatein candidate, patents, and a GMP-certified manufacturing facility in Umeå, with year-end cash expected to be approximately SEK 225M. On June 29, Anna Styrud will return to the company as acting CFO. The strategic review's transition to active inbound interest and the potential divestiture of the Umeå facility could provide a floor under the remaining cash value for the micro-cap entity.
Featured in Issue #18 ·
Sparc Group AB SPARC.ST (SE) · $213 · MCAP $726M · EV $784M
Entrepreneur-driven Nordic roll-up acquiring and operating installation companies in HVAC, electrical, data/telecom, and automation. Founded in 2021, it has bought 90+ firms and employs over 1,000 people across Sweden and Norway.
Sparc Group AB (publ) (SPARC.ST) has initiated a strategic review to evaluate alternatives for growth acceleration and shareholder value maximization. The board of the Nordic roll-up retained Danske Bank A/S NUF as financial and strategic advisor for the process. Potential outcomes include strategic partnerships, structural changes, or equity-related transactions such as a share issue. Since its founding in 2021, Sparc Group has acquired over 90 firms in the HVAC, electrical, data/telecom, and automation sectors across Sweden and Norway. The hiring of a sell-side advisor signals a possible full-company exit, takeover, or material equity raise, creating both M&A optionality and dilution risk as the mandate clarifies the dominant path.
Featured in Issue #18 ·
Done.ai Group AB DONE.ST (SE) · MCAP $84M · EV $100M
EV/GP: 12.7x
Done.ai Group AB is a Swedish technology company listed on Nasdaq Stockholm. Specific business operations are not detailed in the source.
Done.ai Group AB (DONE.ST) has formally resolved to initiate an evaluation of strategic alternatives. The Nasdaq Stockholm-listed technology company announced on May 25 that options under consideration include continued independent execution and other unspecified strategic alternatives. While the board resolution has initiated an active process, no financial advisors have been named and no timeline for the review has been established. This board-initiated strategic review functions similarly to a U.S. exploration of strategic alternatives and signals a potential path toward a full or partial sale, although the lack of advisors or a stated timeline indicates the situation remains in an early stage.
Featured in Issue #17 ·
Diamyd Medical AB DMYD-B.ST (SE) · MCAP $19M · EV $118M
Diamyd Medical is a Swedish biopharmaceutical company developing precision medicine therapies for autoimmune diabetes and other conditions, and operates a manufacturing facility in Umeå.
Diamyd Medical (DMYD-B.ST) is proceeding with a strategic review and evaluating the potential divestment of its Umeå manufacturing facility. Advised by G&W Fondkommission and Vinge, the Swedish biopharmaceutical company also provided updates on its financial position and clinical development plans for its autoimmune diabetes therapies. The review follows the appointment of a new CEO and Chairman in April and occurs as the company’s stock has declined 89% year-to-date. No definitive agreement or firm offer has been reached, and the timing for the evaluation remains uncertain.
Featured in Issue #15 ·
Essity AB ESSITY-B.ST (SE) · MCAP $18.1B · EV $22.6B
Fwd P/E: 13.0x · EV/EBITDA: 6.4x · EV/Sales: 1.5x · EV/GP: 4.6x (FY2026)
Essity is a global hygiene and health company producing personal care, health & medical, professional hygiene, and consumer tissue products. Its Consumer Tissue division manufactures branded toilet paper, paper towels, and facial tissues under premium brands including Lotus, Tempo, and Plenty.
Essity (ESSITY-B.ST) initiated a formal strategic review of its Consumer Tissue division, which accounted for 31% of Group net sales at SEK 43.5bn in 2025. Formally announced at a May 7, 2026 Capital Markets Day, the review assesses potential separation through divestment or a separate public listing. The segment reported an 11.9% EBITA margin, trailing the Group target of greater than 15%. Effective January 1, 2026, the unit assumed end-to-end responsibility for R&D, production, and marketing to function autonomously ahead of structural changes. The division is pivoting from low-margin private label contracts toward premium brands including Lotus, Tempo, and Plenty. A separation could surface value for the company and create a potential spin-off or sale catalyst.
Featured in Issue #15 ·
Teneo AI AB TENEO.ST (SE)
Teneo AI AB provides AI-driven technology solutions. The company is experiencing severe revenue contraction after losing a key customer.
Teneo AI AB (TENEO) is advancing a strategic review and M&A discussions while securing new financing following a sharp decline in Q1 2026 revenue and ARR. The revenue contraction resulted from the loss of a key customer, although gross margins remained strong and cost controls were effective. Market interest in the company’s technology is reported as strong. This distressed strategic review and M&A interest suggests an active restructuring process or sale that could unlock value or wipe out equity.
Featured in Issue #15 ·
Norway 3 situations
Golden Energy Offshore Services GEOS.OL (NO) · MCAP $28M · EV $131M
EV/EBITDA: 23.5x · EV/Sales: 4.2x (FY2026)
Golden Energy Offshore Services is a Norwegian owner and operator of offshore supply vessels servicing the oil and gas industry, listed on Euronext Growth Oslo.
Clear Ocean Partners, holding approximately 40% of Golden Energy Offshore Services (GEOS.OL), and Pelagic Partners, holding much of the remainder, have initiated a strategic review of their shareholding. Potential options include a sale of the shareholding or other transactions, with Clarksons Securities and Wikborg Rein Advokatfirma engaged as advisors. The company has outstanding debt of approximately $46M and a fleet fair market value of approximately $106M following forced vessel sales in late 2025. Recent market performance shows April 2026 utilization at 98% at $19,000/day TCE, up from 84% utilization and $12,300/day TCE in Q1 2026. This review by shareholders controlling a majority stake could trigger a full company sale or control transaction.
Featured in Issue #16 ·
BW Offshore Limited BWO.OL (NO) · MCAP $892M · EV $371M
Fwd P/E: 76.6x · EV/EBITDA: 10.3x · EV/Sales: 5.3x · EV/GP: 13.8x (FY2026)
BW Offshore engineers and operates floating production storage and offloading (FPSO) vessels and floating wind solutions for offshore energy markets. The company has a fleet of FPSOs and approximately 900 employees, listed on the Oslo stock exchange.
BW Offshore (BWO.OL) confirmed in its first quarter 2026 results that the strategic review initiated on 5 December 2025 remains active and progressing. Full-year 2026 EBITDA guidance was revised to USD 310-340 million from USD 340-370 million due to BW Opal downtime and BW Catcher contract amendments. The BW Catcher contract extension adds approximately USD 490 million to the firm operating cash flow backlog and extends the firm term through 31 December 2030. BW Offshore signed a FEED agreement with Equinor for the Bay du Nord FPSO, targeting a Final Investment Decision and potential contract award in early 2027. A quarterly dividend of USD 0.063 per share was declared with an ex-dividend date of 21 May 2026. The active review at the $1.3B-equity operator could result in a full-company sale, merger, or major recapitalization.
Featured in Issue #16 ·
HydrogenPro ASA HYPRO.OL (NO)
HydrogenPro specializes in high-pressure alkaline electrolyzers for green hydrogen production, supplying large-scale plants as an OEM. The company operates globally with a focus on Europe, North America, India, and MENA.
HydrogenPro ASA (HYPRO) has initiated a strategic review to assess alternatives supporting liquidity needs, future growth, and commercial development. The board engaged Clarksons Securities AS as financial advisor as Q1 2026 cash declined to NOK 56 million from NOK 102 million in Q4 2025 alongside a negative EBITDA of NOK -32 million. The company requires near-term financing to support a NOK 1 billion project pipeline expected to reach FID in 2026/2027. HydrogenPro recently secured a strategic OEM partnership with LONGi for 1 GW of manufacturing capacity and mothballed its Tianjin facility. This review signals potential for M&A, a capital raise, or partnership that could materially revalue the equity.
Featured in Issue #15 ·
Singapore 2 situations
CSE Global Limited 544.SI (SG) · MCAP $774M · EV $930M
Fwd P/E: 20.5x · EV/EBITDA: 11.1x · EV/Sales: 1.0x · EV/GP: 3.9x (FY2026)
CSE Global Limited is a Singapore-incorporated technology group providing integrated industrial automation, communications, and environmental engineering solutions primarily to the oil & gas, utilities, and infrastructure sectors globally.
CSE Global Limited (544.SI) issued its fourth monthly update regarding a board-initiated strategic review originally announced on March 5, 2026. Jefferies Singapore Limited is acting as financial adviser to provide recommendations to the board, though no definitive agreement or transaction has materialized from the process. Following earlier updates on April 4 and May 5, the June 5 announcement confirms the review remains ongoing with recommendations expected in due course. The extended review and named role of Jefferies signal a credible transaction process, while the monthly cadence without a conclusion after three months raises questions regarding the status of bid negotiations or potential process stalls.
Featured in Issue #18 ·
CSE Global Limited 544.SI (SG) · MCAP $937M · EV $755M
Fwd P/E: 23.4x · EV/EBITDA: 9.0x · EV/Sales: 0.9x · EV/GP: 3.2x (FY2026)
CSE Global Limited provides integrated systems, automation and communication solutions to industrial and infrastructure clients, focusing on complex operational and safety requirements globally.
CSE Global (544.SI) has appointed Jefferies Singapore Limited as financial adviser for an early-stage strategic review exploring corporate or financial options. The S$1.11B company provides integrated systems, automation, and communication solutions to industrial and infrastructure clients globally. The board stated there is no assurance the review will result in any transaction and cautioned shareholders against taking precipitous action until material developments are announced. The engagement of a global investment bank signals a potentially significant corporate action ahead.
Featured in Issue #15 ·
Germany 2 situations
Thyssenkrupp AG TKA.DE (DE) · MCAP $8.5B · EV $6.6B
EV/EBITDA: 2.8x · EV/Sales: 0.2x · EV/GP: 1.6x (FY2026)
German industrial conglomerate with divisions spanning steel production, marine systems (submarines/naval electronics), and materials distribution/services. CEO López aims to convert the group into a financial holding managing divisional stakes.
thyssenkrupp AG (TKA.DE) is navigating three parallel restructuring vectors in June involving its Steel Europe, TKMS, and Materials Services segments. Deputy supervisory board chairman and IG Metall leader Jürgen Kerner is demanding direct negotiations with CEO López to independently carve out Steel Europe after talks with Jindal Steel stalled in May. Simultaneously, the company expects a late-June decision on a 12-submarine Arctic-capable contract for Canada, where its TKMS unit, which holds a record €20.6B order backlog, is competing against Hanwha Ocean. For its Materials Services division, thyssenkrupp is weighing a late July or early August extraordinary general meeting to approve a spin-off. Financial performance as of the latest quarter showed an improved adjusted EBIT of €198M and a net financial surplus of €2.8B. The convergence of these catalysts makes June a critical month as the union's willingness to accept an independent Steel Europe removes a long-standing political obstacle, shifting the investment focus to execution speed and the Canadian contract verdict.
Featured in Issue #18 ·
Delivery Hero SE DHER.DE (DE) · MCAP $11.8B · EV $10.8B
EV/EBITDA: 2.8x · EV/Sales: 0.6x · EV/GP: 2.8x (FY2026)
Woowa Brothers operates Baedal Minjok (Baemin), the leading food delivery platform in South Korea. Delivery Hero, a German-listed global food delivery group, acquired an 87% stake in Woowa Brothers for $4bn in 2019.
Delivery Hero (DHER.DE) is exploring the sale of its 87% stake in Woowa Brothers, the operator of South Korean food delivery platform Baedal Minjok, for approximately Won8tn ($5.37bn). JPMorgan Chase is acting as sales adviser, with teaser materials circulated to prospective strategic and private equity buyers including Naver. The divestiture is part of a strategic review announced in December 2025 that has already resulted in the $600m sale of Foodpanda Taiwan to Grab. A transaction at the target price would exceed the group’s total market capitalization and crystallize value from the $4bn acquisition of the stake in 2019. CEO Niklas Östberg will step down by March 2027 and will support the ongoing M&A process through that date.
Featured in Issue #16 ·
United Kingdom 2 situations
Aptitude Software Group plc APTD.L (GB) · MCAP $163M · EV $190M
Fwd P/E: NM · EV/EBITDA: 13.3x · EV/Sales: 1.9x · EV/GP: 19.2x (FY2026)
Aptitude Software provides autonomous finance software solutions including the Fynapse intelligent finance data platform, RevStream revenue recognition, and eSuite subscription management. Serves media and enterprise clients with SaaS-based accounting and compliance tools.
Aptitude Software Group plc (APTD.L) has initiated a board-led strategic review including a formal sale process to maximize shareholder value. The review is supported by several major shareholders and aims to secure resources to accelerate the Fynapse platform within the Finance ERP market. Following the initial launch on April 8, the company confirmed the formal sale process is actively underway with the board moving into active solicitation of bids. No definitive timeline has been disclosed, and the board indicated further updates will be provided in due course. The formal launch positions the UK-listed micro-cap for takeout optionality with major shareholder backing, though the absence of a named advisor or timeline indicates the process is early-stage.
Featured in Issue #17 ·
Kazera Global plc KZG.L (GB) · MCAP $15M · EV $23M
Fwd P/E: 0.0x · EV/EBITDA: 7.2x · EV/Sales: 0.3x (LTM)
Kazera Global plc is an AIM-quoted diversified commodity investment company with assets in heavy mineral sands and diamonds in South Africa, and a tantalum/lithium project in Namibia.
Kazera Global (KZG.L) is evaluating strategic pathways for its interest in African Tantalum (Pty) Ltd (Aftan), a tantalum and lithium project in southern Namibia, amid rising interest from third parties and tantalum prices reaching multi-decade highs. The company retains legal title to Aftan shares as security following a binding arbitration victory against Hebei Xinjian Construction. Recent technical analysis identifies potential for dry beneficiation to improve project economics and district-scale exploration upside across 13 known mineralised pegmatites, only three of which have modern resource estimates. Strand Hanson Limited is advising on the review.
Featured in Issue #16 ·
Belgium 2 situations
Syensqo SYENS.BR (BE) · $67.20 · MCAP $8.0B · EV $10.3B
EV/EBITDA: 7.1x
Belgian specialty chemicals and advanced materials company formed via the 2023 spin-off from Solvay. Serves aerospace, automotive, electronics, energy, and consumer end markets.
Syensqo (SYENS.BR) has launched an internal strategic review to explore options, including a potential sale, for its Performance & Care division containing the Novecare and Technology Solutions units. The division generated EUR 2.0 billion in revenue and EUR 358 million in underlying EBITDA in 2025, serving the coatings, personal care, agriculture, and mining end markets. The company, which was spun off from Solvay in 2023, intends to include its Moerdijk, Netherlands production site in any transaction as it seeks to become a pure-play specialty chemicals and advanced materials provider. No timeline or definitive decision for a divestiture has been established. This potential divestiture provides a concrete sum-of-the-parts catalyst, with timing and valuation relative to the parent's current conglomerate discount dependent on the appointment of advisors and a formal sale process launch.
Featured in Issue #17 ·
Syensqo SA/NV SYENS.BR (BE) · MCAP $7.9B · EV $10.7B
Fwd P/E: 20.1x · EV/EBITDA: 8.4x · EV/Sales: 1.6x · EV/GP: 5.6x (FY2026)
Syensqo is a Belgian science and specialty materials company with over 13,000 employees in 30 countries, focused on advanced materials for aerospace, electronics, healthcare, and energy. The Performance & Care segment provides surface chemistry solutions and specialty mining reagents for consumer care, agro, coatings, and mining end markets.
Syensqo (SYENS.BR) initiated a strategic review of its Performance & Care segment to sharpen its portfolio focus and become a pure-play specialty materials company. The review covers the Novecare and Technology Solutions units, which produced €2.0 billion in net sales and €358 million in underlying EBITDA in 2025. Potential outcomes include a sale, spin-off, or other transaction, though there is no defined timetable for completion. This process aims to accelerate growth, sharpen capital allocation, and maximize shareholder value.
Featured in Issue #16 ·
Israel 2 situations
REE Automotive REE (IL) · $0.37 · MCAP $10M · EV $29M
EV/Sales: 3.2x (FY2026)
REE Automotive develops modular electric vehicle platforms with in-wheel motor technology, originally founded in Israel. It went public via SPAC in 2021 and counts major automotive suppliers among its backers.
REE Automotive (REE) has initiated a board-led strategic review to consider a sale, merger, reverse merger, or asset sale. The developer of modular electric vehicle platforms cited ongoing cash pressures and prior going-concern warnings as the rationale for the process. CEO Daniel Barel confirmed the review aims to maximize shareholder value and acknowledged that the company could struggle to continue operating without a transaction. This formal review follows a 2021 SPAC listing at a $3.1B valuation, while REE’s current market capitalization is approximately $13.9M.
Featured in Issue #16 ·
Nano Dimension Ltd. NNDM (IL) · $1.58 · MCAP $331M · EV $137M
Nano Dimension Ltd. is an Israel-based additive manufacturing company focused on 3D-printed electronics and related technologies.
Nano Dimension (NNDM) disclosed during its Q1 2026 earnings call on May 8, 2026, that it has engaged Houlihan Lokey to evaluate strategic alternatives for the company. The review is considering options including a merger, reverse merger, or other structural transactions. Management stated the process is intended to maximize long-term shareholder value. Following the announcement, shares of the Israel-based additive manufacturing company fell 14.59% to $1.58.
Featured in Issue #15 ·
Finland 2 situations
Summa Defence Plc SUMMA.HE (FI) · MCAP $50M · EV $116M
EV/GP: 2.9x
Summa Defence Plc is a Finland-based defence and security technology group focused on maritime, land, and new technologies. Its subsidiary, Summa Energy, provides turnkey industrial-scale solar thermal solutions.
Summa Defence Plc (SUMMA.HE) has initiated a strategic review of its subsidiary Summa Energy Oy to simplify the group structure and focus resources on core maritime, land, and new defence technologies. Summa Energy provides industrial-scale solar thermal solutions under the Savosolar brand and generated €10.1 million in revenue with an EBITA of €-2.7 million for the January–September 2025 period. The review may result in a sale or alternative arrangement, though no decisions or timelines have been confirmed. A potential divestment aims to refocus Summa Defence on higher-margin core segments.
Featured in Issue #16 ·
Summa Defence Plc SUMMA.HE (FI) · €0.7900 · MCAP $460M · EV $116M
Summa Defence Plc is a Finnish defence and security technology group focused on maritime, land, and new technologies, listed on Nasdaq First North in Sweden and Finland.
Summa Defence Plc (SUMMA.HE) has initiated a strategic review of its subsidiaries IntLog Oy, Lightspace Group Inc, Aquamec Oy, and Rasol Oy. The review evaluates alternatives including strategic partnerships, external investments, ownership arrangements, and partial or full divestments of these units. This process is intended to focus the Finnish defence and security technology group on its core maritime, land, and new technology sectors while developing its capital structure. Augment Partners AB is serving as advisor. The company stated the review may not result in any transaction and is part of its normal strategic development.
Featured in Issue #15 ·
France 2 situations
Euroapi S.A. EAPI.PA (FR) · MCAP $166M · EV $193M
EV/EBITDA: 2.8x · EV/Sales: 0.2x · EV/GP: 1.3x (FY2026)
EUROAPI is a leading European active pharmaceutical ingredient (API) manufacturer, supplying small-molecule APIs to pharmaceutical and healthcare companies globally.
EUROAPI (EAPI.PA) is conducting a strategic review of selected industrial assets as part of its FOCUS-27 transformation plan, which targets completion by the end of 2027. The active pharmaceutical ingredient manufacturer confirmed active talks with potential buyers for its Brindisi site in Italy. No final decision has been made regarding a sale of the site. Divestiture proceeds could reshape EUROAPI's balance sheet or fund transformation initiatives.
Featured in Issue #16 ·
Euroapi S.A. EAPI.PA (FR) · €1.45 · MCAP $161M · EV $194M
EV/EBITDA: 2.8x · EV/Sales: 0.2x · EV/GP: 1.3x (FY2026)
EUROAPI is a leading European manufacturer of active pharmaceutical ingredients (APIs). The company operates multiple production sites across Europe, including the Brindisi facility in Italy.
EUROAPI (EAPI.PA) is conducting a review of strategic options for selected industrial assets as part of its FOCUS-27 transformation plan, which targets completion by the end of 2027. The company confirmed it is in active talks with potential buyers regarding its manufacturing facility in Brindisi, Italy, though no final decision has been made. This ongoing strategic review and confirmed buyer talks for the specific site could lead to a material asset divestiture to generate cash and reshape the company's industrial footprint.
Featured in Issue #15 ·
United Kingdom 1 situations
Litigation Capital Management Limited LIT.L (UK) · MCAP $4M · EV $50M
Fwd P/E: 1.3x (FY2027)
Litigation Capital Management is an alternative asset manager specializing in dispute financing solutions internationally, providing capital for litigation and arbitration cases in exchange for a share of the proceeds.
Litigation Capital Management Limited (LIT.L) is conducting a strategic review with advisor Cavendish to resolve its long-term capital position. The company secured an extension of its debt covenant waiver with lender Northleaf from May 30, 2026, to June 30, 2026, which carries a 2.00% per annum interest penalty but no additional waiver fee. Simultaneously, LCM reported expected material write-downs in its next financial statements following negative developments on two case investments representing A$9M in invested capital. The 30-day waiver extension to June 30 acts as a ticking clock on the strategic review, as failure to announce a recapitalization or sale resolution by expiry could trigger a lender-enforced outcome.
Featured in Issue #18 ·
Switzerland 1 situations
LEM Holding SA LEHN.SW (CH) · MCAP $701M · EV $537M
Fwd P/E: 28.8x · EV/EBITDA: 6.3x · EV/Sales: 1.4x · EV/GP: 3.6x (FY2027)
LEM Holding SA manufactures current and voltage sensors used in industrial automation, automotive, renewable energy, rail, and data center applications. It serves global customers across China, Asia, EMEA, and the Americas.
LEM Holding SA (LEHN) has launched a strategic review of the company following inbound interest from potential partners. The Swiss manufacturer of current and voltage sensors reported FY 2025/26 sales slipped 6.3% to CHF 287.7M, though EBIT rose 29.2% and free cash flow more than doubled. Results were supported by a Q4 book-to-bill of 1.16 driven by demand for data center infrastructure and industrial automation. The company has a market capitalization of approximately CHF 373.7M. This board-initiated process establishes a catalyst for a formal sale or take-private offer, where a CHF 355 analyst price target versus the current market capitalization suggests a potential premium if a deal materializes.
Featured in Issue #17 ·
Bermuda 1 situations
Golar LNG Ltd GLNG (BM) · $52.36 · MCAP $5.3B · EV $5.4B
Fwd P/E: 54.3x · EV/EBITDA: 27.1x · EV/Sales: 12.6x · EV/GP: 26.9x (FY2026)
Golar LNG Limited is a Bermuda-domiciled owner and operator of floating liquefied natural gas (FLNG) vessels, primarily the FLNG Hilli and FLNG Gimi, which liquefy and export natural gas under long-term contracts.
Golar Lng Ltd (GLNG) has engaged Goldman Sachs to evaluate strategic alternatives for the company. Disclosed as a highlight in its Q1 2026 interim results, the board-initiated review creates a catalyst for potential value realization via a sale, merger, or go-private transaction. Golar reported Q1 2026 net income of $84M, Adjusted EBITDA of $106M, and Total Golar Cash of $1.0B. The company currently operates the FLNG vessels Hilli and Gimi, with a third MKII unit under conversion and plans to order a fourth FLNG in 2026. Recent corporate activity includes the divestment of an investment in OLT Offshore Toscana S.p.A. and the exit of its FSRU O&M contract.
Featured in Issue #16 ·
Argentina 1 situations
Bioceres Crop Solutions Corp. BIOX (AR) · $0.4290 · MCAP $27M · EV $526M
Fwd P/E: 8.6x · EV/EBITDA: 10.1x · EV/Sales: 1.4x · EV/GP: 3.6x (FY2027)
Develops and commercializes agricultural productivity solutions including crop protection, seeds and integrated products, and crop nutrition designed to regenerate ecosystems and improve climate resilience.
Bioceres Crop Solutions Corp. (BIOX) is conducting a strategic review of continuing operations focused on organizational streamlining and capital allocation optimization. The review follows the January 2026 foreclosure auction and classification of the Pro Farm Group subsidiary as discontinued operations. In the fiscal third quarter, total revenues declined 23% year-over-year to $39.4 million with a net loss of $10.0 million and negative adjusted EBITDA of $(0.6) million. Bioceres is currently advancing liability management initiatives, including debt reprofiling and a voluntary bond maturity extension in Argentina. The strategic review signals potential M&A, divestiture, or recapitalization catalysts as management refocuses on core operations.
Featured in Issue #15 ·
Hong Kong 1 situations
CK Hutchison Holdings Limited 0001.HK (HK) · MCAP $13.8B · EV $50.2B
Fwd P/E: 10.9x · EV/EBITDA: 4.2x · EV/Sales: 1.0x · EV/GP: 5.6x (FY2026)
CK Hutchison Holdings is a Hong Kong-based multinational conglomerate with diversified operations spanning ports, retail, infrastructure, and telecommunications across Europe, Asia, and beyond.
CK Hutchison (0001.HK) has paused the planned spin-off of its telecommunications unit, which was previously valued at approximately $20 billion and intended for a London IPO with a secondary Hong Kong listing. The conglomerate is pivoting to a divestiture strategy focused on individual market-by-market asset sales to realize break-up value. This shift follows the agreed sale of the company’s 49% stake in a British joint venture with Vodafone, which was a core component of the original spin-off package. Potential transactions under the new private-market process include a combination of the Italian unit Wind Tre with Iliad's Italian business. The transition to a piecemeal divestiture program creates a multi-catalyst deal stack while changing the transaction timeline, valuation benchmarks, and risk profile. Execution of these targeted sales introduces uncertainty due to potential regulatory hurdles in each jurisdiction.
Featured in Issue #15 ·
India 1 situations
Kalpataru Limited 544423.BO (IN) · ₹3.95 · MCAP $813M
Mumbai-based real estate developer focused on residential and commercial projects; recently completed a Korum Mall demerger.
Kalpataru Ltd (544423.BO) filed an announcement under Regulation 30 (LODR) with the BSE regarding a corporate restructuring. The filing indicates the company has formally initiated a process to evaluate strategic alternatives. No specifics concerning the form of restructuring, advisors, or timeline were disclosed. The board-initiated announcement could signal a potential sale, spin-off, or debt reorganization for the Indian small-cap.
Featured in Issue #15 ·
Japan 1 situations
Seven & i Holdings Co Ltd 3382.T (JP) · $11.83 · MCAP $27.1B · EV $8779.8B
EV/EBITDA: 10.8x · EV/Sales: 0.9x · EV/GP: 3.3x (FY2027)
Seven & i Holdings operates the global 7-Eleven convenience store network across Japan and North America, alongside the Ito-Yokado supermarket chain and financial services. The group is streamlining its portfolio to focus on the higher-margin convenience format.
Seven & i Holdings Co Ltd (3382.T) is conducting a portfolio strategic review to enhance capital efficiency and return on equity by focusing on its high-return global 7-Eleven convenience store network. Under shareholder pressure to concentrate on the cash-generating 7-Eleven brand in Japan and North America, management has been trimming non-core assets including the Sogo & Seibu department store banners. The group's medium-term plan includes targets for operating profit expansion and prioritizes capital allocation for convenience operations. This streamlining signals potential further divestitures or structural changes at the retailer, which also operates the Ito-Yokado supermarket chain and financial services.
Featured in Issue #15 ·
Get the full Special Situations Digest weekly
300+ situations across 30+ countries every Sunday. Excel/PDF/JSON exports. 14-day free trial.
Start 14-day free trial →